Union Bancaire Privee UBP SA Makes New Investment in BioNTech SE (NASDAQ:BNTX)

Union Bancaire Privee UBP SA purchased a new stake in BioNTech SE (NASDAQ:BNTX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,500 shares of the company’s stock, valued at approximately $282,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC increased its stake in shares of BioNTech by 412.3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after purchasing an additional 33,375 shares in the last quarter. Mirabaud & Cie SA acquired a new position in shares of BioNTech in the fourth quarter worth $684,000. Atomi Financial Group Inc. raised its holdings in shares of BioNTech by 6.7% in the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company’s stock worth $414,000 after acquiring an additional 229 shares during the last quarter. Retireful LLC acquired a new stake in shares of BioNTech during the fourth quarter valued at $260,000. Finally, GAMMA Investing LLC boosted its stake in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Price Performance

BNTX opened at $124.30 on Wednesday. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $29.80 billion, a price-to-earnings ratio of -59.19 and a beta of 0.18. The company has a fifty day simple moving average of $116.50 and a 200 day simple moving average of $106.57.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period in the previous year, the company earned $0.73 earnings per share. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities research analysts expect that BioNTech SE will post -3.77 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on BNTX. Berenberg Bank initiated coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. TD Cowen reduced their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. JPMorgan Chase & Co. decreased their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 26th. Finally, HSBC raised their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.